Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Aragon

- PMLiVE

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

- PMLiVE

J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

- PMLiVE

Major prostate cancer screening trial launched in UK

The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

- PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

The drug is the first IL-23 inhibitor approved for children from the age of six

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

- PMLiVE

Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis

The Stelara biosimilar now offers all dosage forms and strengths of its reference product

- PMLiVE

J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

More than 2.5 million people in Europe are affected by the inflammatory bowel disease

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

- PMLiVE

Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

The inflammatory condition affects approximately 30% of psoriasis patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links